Predictive Oncology raised $343.5 million for the acquisition of ATH tokens.

robot
Abstract generation in progress

Predictive Oncology successfully raised 343.5 million USD through a PIPE funding round to purchase ATH tokens, aimed at strengthening its digital asset reserve strategy. The funding consists of 50.8 million USD in cash and 292.7 million USD in cryptocurrency, including preemptive rights to purchase ATH tokens.

Under the leadership of CEO Carl Schwartz, the company expands into blockchain technology for distributed computing, while enhancing liquidity and interaction within the Aethir ecosystem. This move represents a step forward in integrating blockchain and AI into the field of precision medicine, aiming to reduce costs and scale healthcare.

Although there has been no official response from experts, the online community on Twitter and Reddit is actively discussing the potential application of blockchain in healthcare, considering it a promising trend that connects digital technology with biotechnology.

ATH-1.89%
View Original
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
0/400
No comments
Trade Crypto Anywhere Anytime
qrCode
Scan to download Gate App
Community
English
  • 简体中文
  • English
  • Tiếng Việt
  • 繁體中文
  • Español
  • Русский
  • Français (Afrique)
  • Português (Portugal)
  • Bahasa Indonesia
  • 日本語
  • بالعربية
  • Українська
  • Português (Brasil)